Cargando…
Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens
Mucosa-associated invariant T (MAIT) cells are MR1-restricted, innate-like T lymphocytes with tremendous antibacterial and immunomodulatory functions. Additionally, MAIT cells sense and respond to viral infections in an MR1-independent fashion. However, whether they can be directly targeted in immun...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337970/ https://www.ncbi.nlm.nih.gov/pubmed/37384813 http://dx.doi.org/10.1371/journal.ppat.1011485 |
_version_ | 1785071532095045632 |
---|---|
author | Rashu, Rasheduzzaman Ninkov, Marina Wardell, Christine M. Benoit, Jenna M. Wang, Nicole I. Meilleur, Courtney E. D’Agostino, Michael R. Zhang, Ali Feng, Emily Saeedian, Nasrin Bell, Gillian I. Vahedi, Fatemeh Hess, David A. Barr, Stephen D. Troyer, Ryan M. Kang, Chil-Yong Ashkar, Ali A. Miller, Matthew S. Haeryfar, S. M. Mansour |
author_facet | Rashu, Rasheduzzaman Ninkov, Marina Wardell, Christine M. Benoit, Jenna M. Wang, Nicole I. Meilleur, Courtney E. D’Agostino, Michael R. Zhang, Ali Feng, Emily Saeedian, Nasrin Bell, Gillian I. Vahedi, Fatemeh Hess, David A. Barr, Stephen D. Troyer, Ryan M. Kang, Chil-Yong Ashkar, Ali A. Miller, Matthew S. Haeryfar, S. M. Mansour |
author_sort | Rashu, Rasheduzzaman |
collection | PubMed |
description | Mucosa-associated invariant T (MAIT) cells are MR1-restricted, innate-like T lymphocytes with tremendous antibacterial and immunomodulatory functions. Additionally, MAIT cells sense and respond to viral infections in an MR1-independent fashion. However, whether they can be directly targeted in immunization strategies against viral pathogens is unclear. We addressed this question in multiple wild-type and genetically altered but clinically relevant mouse strains using several vaccine platforms against influenza viruses, poxviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), a riboflavin-based MR1 ligand of bacterial origin, can synergize with viral vaccines to expand MAIT cells in multiple tissues, reprogram them towards a pro-inflammatory MAIT1 phenotype, license them to bolster virus-specific CD8(+) T cell responses, and potentiate heterosubtypic anti-influenza protection. Repeated 5-OP-RU administration did not render MAIT cells anergic, thus allowing for its inclusion in prime-boost immunization protocols. Mechanistically, tissue MAIT cell accumulation was due to their robust proliferation, as opposed to altered migratory behavior, and required viral vaccine replication competency and Toll-like receptor 3 and type I interferon receptor signaling. The observed phenomenon was reproducible in female and male mice, and in both young and old animals. It could also be recapitulated in a human cell culture system in which peripheral blood mononuclear cells were exposed to replicating virions and 5-OP-RU. In conclusion, although viruses and virus-based vaccines are devoid of the riboflavin biosynthesis machinery that supplies MR1 ligands, targeting MR1 enhances the efficacy of vaccine-elicited antiviral immunity. We propose 5-OP-RU as a non-classic but potent and versatile vaccine adjuvant against respiratory viruses. |
format | Online Article Text |
id | pubmed-10337970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-103379702023-07-13 Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens Rashu, Rasheduzzaman Ninkov, Marina Wardell, Christine M. Benoit, Jenna M. Wang, Nicole I. Meilleur, Courtney E. D’Agostino, Michael R. Zhang, Ali Feng, Emily Saeedian, Nasrin Bell, Gillian I. Vahedi, Fatemeh Hess, David A. Barr, Stephen D. Troyer, Ryan M. Kang, Chil-Yong Ashkar, Ali A. Miller, Matthew S. Haeryfar, S. M. Mansour PLoS Pathog Research Article Mucosa-associated invariant T (MAIT) cells are MR1-restricted, innate-like T lymphocytes with tremendous antibacterial and immunomodulatory functions. Additionally, MAIT cells sense and respond to viral infections in an MR1-independent fashion. However, whether they can be directly targeted in immunization strategies against viral pathogens is unclear. We addressed this question in multiple wild-type and genetically altered but clinically relevant mouse strains using several vaccine platforms against influenza viruses, poxviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), a riboflavin-based MR1 ligand of bacterial origin, can synergize with viral vaccines to expand MAIT cells in multiple tissues, reprogram them towards a pro-inflammatory MAIT1 phenotype, license them to bolster virus-specific CD8(+) T cell responses, and potentiate heterosubtypic anti-influenza protection. Repeated 5-OP-RU administration did not render MAIT cells anergic, thus allowing for its inclusion in prime-boost immunization protocols. Mechanistically, tissue MAIT cell accumulation was due to their robust proliferation, as opposed to altered migratory behavior, and required viral vaccine replication competency and Toll-like receptor 3 and type I interferon receptor signaling. The observed phenomenon was reproducible in female and male mice, and in both young and old animals. It could also be recapitulated in a human cell culture system in which peripheral blood mononuclear cells were exposed to replicating virions and 5-OP-RU. In conclusion, although viruses and virus-based vaccines are devoid of the riboflavin biosynthesis machinery that supplies MR1 ligands, targeting MR1 enhances the efficacy of vaccine-elicited antiviral immunity. We propose 5-OP-RU as a non-classic but potent and versatile vaccine adjuvant against respiratory viruses. Public Library of Science 2023-06-29 /pmc/articles/PMC10337970/ /pubmed/37384813 http://dx.doi.org/10.1371/journal.ppat.1011485 Text en © 2023 Rashu et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Rashu, Rasheduzzaman Ninkov, Marina Wardell, Christine M. Benoit, Jenna M. Wang, Nicole I. Meilleur, Courtney E. D’Agostino, Michael R. Zhang, Ali Feng, Emily Saeedian, Nasrin Bell, Gillian I. Vahedi, Fatemeh Hess, David A. Barr, Stephen D. Troyer, Ryan M. Kang, Chil-Yong Ashkar, Ali A. Miller, Matthew S. Haeryfar, S. M. Mansour Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens |
title | Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens |
title_full | Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens |
title_fullStr | Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens |
title_full_unstemmed | Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens |
title_short | Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens |
title_sort | targeting the mr1-mait cell axis improves vaccine efficacy and affords protection against viral pathogens |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337970/ https://www.ncbi.nlm.nih.gov/pubmed/37384813 http://dx.doi.org/10.1371/journal.ppat.1011485 |
work_keys_str_mv | AT rashurasheduzzaman targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT ninkovmarina targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT wardellchristinem targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT benoitjennam targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT wangnicolei targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT meilleurcourtneye targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT dagostinomichaelr targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT zhangali targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT fengemily targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT saeediannasrin targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT bellgilliani targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT vahedifatemeh targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT hessdavida targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT barrstephend targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT troyerryanm targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT kangchilyong targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT ashkaralia targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT millermatthews targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens AT haeryfarsmmansour targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens |